Consensus Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
28.48 USD +1.71% Intraday chart for Protagonist Therapeutics, Inc. -1.39% +24.20%

Evolution of the average Target Price on Protagonist Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e790.Y3RAYP5Pbo4qW0U3rdCfADpvqUDdopWyvI6fLsWF89Y.BwQjIs0jJuESGQlf9JfuRnxYnSW7kOGChejddpT0loAtPzYakhUGt3IsdQ~0a0d2a099f4f66833f213d8189a25479
JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating MT
Capital One Starts Protagonist Therapeutics With Overweight Rating, $32 Price Target MT
JPMorgan Lowers Protagonist Therapeutics' Price Target to $34 From $36, Keeps Overweight Rating MT
JMP Securities Raises Protagonist Therapeutics' Price Target to $35 From $28, Keeps Market Outperform Rating MT
HC Wainwright Adjusts Price Target on Protagonist Therapeutics to $38 From $33, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $28 From $31, Maintains Market Outperform Rating MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $31 From $21, Maintains Market Outperform Rating MT
HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating MT
JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price Target MT
Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating MT
SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outperform Rating MT
BTIG Initiates Protagonist Therapeutics at Buy With $55 Price Target MT
JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps Market Outperform Rating MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $60 From $47, Maintains Market Outperform Rating MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $47 From $55, Maintains Market Outperform Rating MT
PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $50 from $35, Keeps Outperform Rating MT
PROTAGONIST THERAPEUTICS : JPMorgan Upgrades Protagonist Therapeutics to Overweight From Neutral, Sets Price Target at $55 MT
ANALYST RECOMMENDATIONS : Cigna, Halliburton, Nike, Nio, Trex... Our Logo
PROTAGONIST THERAPEUTICS : Northland Capital Markets Upgrades Protagonist Therapeutics to Outperform Rating From Market Perform, Lifts Price Target to $40 From $25 MT
PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics to $47 From $55, Maintains Market Outperform Rating MT
PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $35 from $50, Keeps Outperform Rating MT
PROTAGONIST THERAPEUTICS : HC Wainwright Adjusts Protagonist Therapeutics' Price Target to $50 from $60, Keeps Buy Rating MT
PROTAGONIST THERAPEUTICS : JPMorgan Downgrades Protagonist Therapeutics to Neutral From Overweight, Price Target at $49 MT
PROTAGONIST THERAPEUTICS : Northland Capital Downgrades Protagonist Therapeutics to Market Perform from Outperform, Adjusts PT to $25 from $52 MT
PROTAGONIST THERAPEUTICS : HC Wainwright Adjusts Protagonist Therapeutics' Price Target to $60 From $50, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
28.48 USD
Average target price
43 USD
Spread / Average Target
+50.98%
High Price Target
52 USD
Spread / Highest target
+82.58%
Low Price Target
37 USD
Spread / Lowest Target
+29.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Protagonist Therapeutics, Inc.

JPMorgan Chase
Capital One Securities
JMP Securities
HC Wainwright
Piper Sandler
SVB Leerink
BTIG
Northland Securities
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock Protagonist Therapeutics, Inc. - Nasdaq
  4. Consensus Protagonist Therapeutics, Inc.